Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of pharmacokinetics (PK) and safety of the Medtronic endeavor drug (ABT-578) [zotarolimus] eluting coronary stent system in de novo native coronary artery lesions.

Next Previous
X
Search
Trial Profile

Evaluation of pharmacokinetics (PK) and safety of the Medtronic endeavor drug (ABT-578) [zotarolimus] eluting coronary stent system in de novo native coronary artery lesions.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Myocardial infarction
  • Focus Pharmacokinetics
  • Acronyms ENDEAVOR-PK
  • Sponsors Medtronic

    • Most Recent Events

    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 15 Mar 2010 Five-year pooled analysis of ENDEAVOR programme including 3-year results from this trial presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC), according to a Medtronic media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top